登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《MedRixv，3月3日，The level of plasma C-reactive protein is closely related to the liver injury in patients with COVID-19》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-04

  • The level of plasma C-reactive protein is closely related to the liver injury in patients with COVID-19

    Lu Li, Shuang Li, Manman Xu, Sujun Zheng, Zhongping Duan, Yu Chen, Junfeng Li

    doi: https://doi.org/10.1101/2020.02.28.20028514

    Abstract

    Aim: Coronavirus disease 2019 (COVID-19) has rapidly become the most severe public health issue all over the world. Despite acute respiratory failure, liver dysfunction has also been observed in clinical settings This study aimed to investigate the factors involved with hepatic injury in COVID-19 patients. Methods: A total of 26 hospitalized patients who were diagnosed with COVID-19 treated at Beijing Youan Hospital were retrospectively analyzed. According to the diagnostic criteria, they were divided into mild group (n=3), ordinary group (n=6), serious group (n=11) and critical group (n=6). Blood count, blood chemistry, coagulation test, liver and renal function, C-reactive protein, procalcitonin, lactic acid, cardiac markers and arterial partial pressure was compared between these groups. Independent risk factors of ALT increase was selected.

    *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.

  • 原文来源：https://www.medrxiv.org/content/10.1101/2020.02.28.20028514v1
14浏览量
原文链接
相关报告

  • 《LANCET，3月4日，Liver injury in COVID-19: management and challenges》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-05
    • Liver injury in COVID-19: management and challenges Chao Zhang, Lei Shi, Fu-Sheng Wang Published:March 04, 2020DOI:https://doi.org/10.1016/S2468-1253(20)30057-1 In December, 2019, an outbreak of a novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], previously 2019-nCoV) started in Wuhan, China, and has since become a global threat to human health. The number of confirmed cases of 2019 coronavirus disease (COVID-19) has reached 87?137 worldwide as of March 1, 2020, according to WHO COVID-19 situation report 41; most of these patients are in Wuhan, China. Many cases of COVID-19 are acute and resolve quickly, but the disease can also be fatal, with a mortality rate of around 3%. Onset of severe disease can result in death due to massive alveolar damage and progressive respiratory failure.
    132浏览量
    原文链接

  • 《 MedRixv，2月27日，Clinical Features of COVID-19 Related Liver Damage》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-02-28
    • Clinical Features of COVID-19 Related Liver Damage Zhenyu Fan, Liping Chen, Jun Li, Cheng Tian, Yajun Zhang, Shaoping Huang, Zhanju Liu, Jilin Cheng doi: https://doi.org/10.1101/2020.02.26.20026971 Abstract BACKGROUND: A recent outbreak of SARS-CoV-2 infection occurs mainly in China, with rapidly increasing the number of cases (namely COVID-19). Abnormal liver functions are frequently present in these patients, here we aimed to clarify the clinical features of COVID-19-related liver damage to provide some references for the clinical treatment. METHODS: In this retrospective, single-center study, we included all confirmed COVID-19 cases in Shanghai Public Health Clinical Center from January 20 to January 31, 2020. The outcomes were followed up until February 19, 2020. A total of 148 cases were analyzed for clinical features, laboratory parameters (including liver function tests), medications and the length of stay. FINDINGS: Of 148 confirmed SARS-CoV-2-infected patients, 49.3% were females and 50.7% were males. The median age was 50.5 years (interquartile range, 36-64). Patients had clinical manifestations of fever (70.1%), cough (45.3%), expectoration (26.7%) at admission. 75 patients (50.7%) showed abnormal liver functions at admission, characterized by an increased of 具体那些升高alt, ast, GGT, AKP等. Patients (n = 75) who had elevated liver function index were more likely to have a moderate-high degree fever (44% vs 27.4%; p = 0.035) and significantly present in male patients (62.67% vs 38.36%; p = 0.005). The numbers of CD4+ and CD8+ T cells were significantly lower in abnormal liver function group than those in normal liver function group. There was no statistical difference in prehospital medications between normal and abnormal liver function groups, while the utilization rate of lopinavir/ritonavir after admission was significantly higher in patients with emerging liver injury than that in patients with normal liver functions. Importantly, the emerging abnormal liver functions after admission caused a prolonged length of stay. INTERPRETATION: SARS-CoV-2 may cause the liver function damage and the Lopinavir/ritonavir should be applied carefully for the treatment of COVID-19. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    82浏览量
    原文链接